Investigational Drug Information for Fluoropyrimidine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Fluoropyrimidine?
Fluoropyrimidine is an investigational drug.
There have been 279 clinical trials for Fluoropyrimidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 30th 2018.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Stomach Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Eli Lilly and Company, and Hoffmann-La Roche.
There are nine hundred and twenty-one US patents protecting this investigational drug and eight international patents.
Summary for Fluoropyrimidine
| US Patents | 921 |
| International Patents | 8,822 |
| US Patent Applications | 3,041 |
| WIPO Patent Applications | 1,634 |
| Japanese Patent Applications | 1,094 |
| Clinical Trial Progress | Phase 3 (2018-07-30) |
| Vendors | 74 |
Recent Clinical Trials for Fluoropyrimidine
| Title | Sponsor | Phase |
|---|---|---|
| Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy | CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino | Phase 2 |
| Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy | Laboratory Molecular Oncology Candiolo Cancer Institute IRCCS - Candiolo (Torino) | Phase 2 |
| Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy | Ospedale Policlinico San Martino | Phase 2 |
Clinical Trial Summary for Fluoropyrimidine
Top disease conditions for Fluoropyrimidine
Top clinical trial sponsors for Fluoropyrimidine
US Patents for Fluoropyrimidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fluoropyrimidine | See Plans and Pricing | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | See Plans and Pricing |
| Fluoropyrimidine | See Plans and Pricing | Combination therapies for cancer | MERCK SHARP & DOHME CORP. (Rahway, NJ) NOVARTIS AG (Basel, CH) | See Plans and Pricing |
| Fluoropyrimidine | See Plans and Pricing | Tapered looped suture | Covidien LP (Mansfield, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fluoropyrimidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fluoropyrimidine | World Intellectual Property Organization (WIPO) | WO2013071079 | 2031-11-09 | See Plans and Pricing |
| Fluoropyrimidine | European Patent Office | EP3003316 | 2033-05-31 | See Plans and Pricing |
| Fluoropyrimidine | Spain | ES2822665 | 2033-05-31 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
